Skip to main content
Top
Published in: BMC Immunology 1/2009

Open Access 01-12-2009 | Research article

Dynamics of central and peripheral immunomodulation in a murine glioma model

Authors: Benjamin C Kennedy, Lisa M Maier, Randy D'Amico, Christopher E Mandigo, Elizabeth J Fontana, Allen Waziri, Marcela C Assanah, Peter Canoll, Richard CE Anderson, David E Anderson, Jeffrey N Bruce

Published in: BMC Immunology | Issue 1/2009

Login to get access

Abstract

Background

Immunosuppression by gliomas contributes to tumor progression and treatment resistance. It is not known when immunosuppression occurs during tumor development but it likely involves cross-talk among tumor cells, tumor-associated macrophages and microglia (TAMs), and peripheral as well as tumor-infiltrating lymphocytes (TILs).

Results

We have performed a kinetic study of this immunomodulation, assessing the dynamics of immune infiltration and function, within the central nervous system (CNS) and peripherally. PDGF-driven murine glioma cells were injected into the white matter of 13 mice. Four mice were sacrificed 13 days post-injection (dpi), four mice at 26 dpi, and five mice at 40 dpi. Using multiparameter flow cytometry, splenic T cells were assessed for FoxP3 expression to identify regulatory T cells (Tregs) and production of IFN-γ and IL-10 after stimulation with PMA/ionomycin; within the CNS, CD4+ TILs were quantified, and TAMs were quantified and assessed for TNF-α and IL-10 production after stimulation with LPS. Peripheral changes associated with tumor development were noted prior to effects within the CNS. The percentage of FoxP3+ regulatory T cells (Tregs) increased by day 26, with elevated frequencies throughout the duration of the study. This early increase in Tregs was paralleled by an increase in IL-10 production from Tregs. At the final time points examined (tumor morbidity or 40 dpi), there was an increase in the frequency of TAMs with decreased capacity to secrete TNF-α. An increase in TIL frequency was also observed at these final time points.

Conclusion

These data provide insight into the kinetics of the immunosuppressive state associated with tumor growth in a murine model of human gliomas. Functional impairment of TAMs occurs relatively late in the course of GBM tumor growth, potentially providing a window of opportunity for therapeutic strategies directed towards preventing their functional impairment.
Appendix
Available only for authorised users
Literature
2.
go back to reference Radhakrishnan K, Mokri B, Parisi JE, O'Fallon WM, Sunku J, Kurland LT: The trends in incidence of primary brain tumors in the population of Rochester, Minnesota. Ann Neurol. 1995, 37: 67-73. 10.1002/ana.410370113.CrossRefPubMed Radhakrishnan K, Mokri B, Parisi JE, O'Fallon WM, Sunku J, Kurland LT: The trends in incidence of primary brain tumors in the population of Rochester, Minnesota. Ann Neurol. 1995, 37: 67-73. 10.1002/ana.410370113.CrossRefPubMed
3.
go back to reference Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH: Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res. 2003, 9: 4247-54.PubMed Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH: Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res. 2003, 9: 4247-54.PubMed
4.
go back to reference Kushen MC, Sonabend AM, Lesniak MS: Current immunotherapeutic strategies for central nervous system tumors. Surg Oncol Clin N Am. 2007, 16: 987-1004. 10.1016/j.soc.2007.07.003. xiiPubMedCentralCrossRefPubMed Kushen MC, Sonabend AM, Lesniak MS: Current immunotherapeutic strategies for central nervous system tumors. Surg Oncol Clin N Am. 2007, 16: 987-1004. 10.1016/j.soc.2007.07.003. xiiPubMedCentralCrossRefPubMed
5.
go back to reference Finn OJ: Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 2003, 3: 630-41. 10.1038/nri1150.CrossRefPubMed Finn OJ: Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 2003, 3: 630-41. 10.1038/nri1150.CrossRefPubMed
7.
go back to reference Hussain SF, Heimberger AB: Immunotherapy for human glioma: innovative approaches and recent results. Expert Rev Anticancer Ther. 2005, 5: 777-90. 10.1586/14737140.5.5.777.CrossRefPubMed Hussain SF, Heimberger AB: Immunotherapy for human glioma: innovative approaches and recent results. Expert Rev Anticancer Ther. 2005, 5: 777-90. 10.1586/14737140.5.5.777.CrossRefPubMed
8.
go back to reference Sikorski CW, Lesniak MS: Immunotherapy for malignant glioma: current approaches and future directions. Neurol Res. 2005, 27: 703-16. 10.1179/016164105X49481.CrossRefPubMed Sikorski CW, Lesniak MS: Immunotherapy for malignant glioma: current approaches and future directions. Neurol Res. 2005, 27: 703-16. 10.1179/016164105X49481.CrossRefPubMed
9.
go back to reference Barker CF, Billingham RE: Immunologically privileged sites. Adv Immunol. 1977, 25: 1-54. 10.1016/S0065-2776(08)60930-X.CrossRefPubMed Barker CF, Billingham RE: Immunologically privileged sites. Adv Immunol. 1977, 25: 1-54. 10.1016/S0065-2776(08)60930-X.CrossRefPubMed
10.
go back to reference Becher B, Prat A, Antel JP: Brain-immune connection: immuno-regulatory properties of CNS-resident cells. Glia. 2000, 29: 293-304. 10.1002/(SICI)1098-1136(20000215)29:4<293::AID-GLIA1>3.0.CO;2-A.CrossRefPubMed Becher B, Prat A, Antel JP: Brain-immune connection: immuno-regulatory properties of CNS-resident cells. Glia. 2000, 29: 293-304. 10.1002/(SICI)1098-1136(20000215)29:4<293::AID-GLIA1>3.0.CO;2-A.CrossRefPubMed
11.
go back to reference Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC: CNS immune privilege: hiding in plain sight. Immunol Rev. 2006, 213: 48-65. 10.1111/j.1600-065X.2006.00441.x.PubMedCentralCrossRefPubMed Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC: CNS immune privilege: hiding in plain sight. Immunol Rev. 2006, 213: 48-65. 10.1111/j.1600-065X.2006.00441.x.PubMedCentralCrossRefPubMed
12.
go back to reference Hickey WF: Basic principles of immunological surveillance of the normal central nervous system. Glia. 2001, 36: 118-24. 10.1002/glia.1101.CrossRefPubMed Hickey WF: Basic principles of immunological surveillance of the normal central nervous system. Glia. 2001, 36: 118-24. 10.1002/glia.1101.CrossRefPubMed
13.
go back to reference Watters JJ, Schartner JM, Badie B: Microglia function in brain tumors. J Neurosci Res. 2005, 81: 447-55. 10.1002/jnr.20485.CrossRefPubMed Watters JJ, Schartner JM, Badie B: Microglia function in brain tumors. J Neurosci Res. 2005, 81: 447-55. 10.1002/jnr.20485.CrossRefPubMed
14.
go back to reference Kim R, Emi M, Tanabe K: Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology. 2006, 119: 254-64. 10.1111/j.1365-2567.2006.02430.x.PubMedCentralCrossRefPubMed Kim R, Emi M, Tanabe K: Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology. 2006, 119: 254-64. 10.1111/j.1365-2567.2006.02430.x.PubMedCentralCrossRefPubMed
15.
go back to reference Badie B, Schartner J: Role of microglia in glioma biology. Microsc Res Tech. 2001, 54: 106-13. 10.1002/jemt.1125.CrossRefPubMed Badie B, Schartner J: Role of microglia in glioma biology. Microsc Res Tech. 2001, 54: 106-13. 10.1002/jemt.1125.CrossRefPubMed
16.
go back to reference Kostianovsky AM, Maier LM, Anderson RC, Bruce JN, Anderson DE: Astrocytic Regulation of Human Monocytic/Microglial Activation. J Immunol. 181 (8): 5425-5432. Kostianovsky AM, Maier LM, Anderson RC, Bruce JN, Anderson DE: Astrocytic Regulation of Human Monocytic/Microglial Activation. J Immunol. 181 (8): 5425-5432.
17.
go back to reference Hussain SF, Yang D, Suki D, Grimm E, Heimberger AB: Innate immune functions of microglia isolated from human glioma patients. J Transl Med. 2006, 4: 15-10.1186/1479-5876-4-15.PubMedCentralCrossRefPubMed Hussain SF, Yang D, Suki D, Grimm E, Heimberger AB: Innate immune functions of microglia isolated from human glioma patients. J Transl Med. 2006, 4: 15-10.1186/1479-5876-4-15.PubMedCentralCrossRefPubMed
18.
go back to reference Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB: The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol. 2006, 8: 261-79. 10.1215/15228517-2006-008.PubMedCentralCrossRefPubMed Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB: The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol. 2006, 8: 261-79. 10.1215/15228517-2006-008.PubMedCentralCrossRefPubMed
19.
go back to reference Schartner JM, Hagar AR, Van Handel M, Zhang L, Nadkarni N, Badie B: Impaired capacity for upregulation of MHC class II in tumor-associated microglia. Glia. 2005, 51: 279-85. 10.1002/glia.20201.CrossRefPubMed Schartner JM, Hagar AR, Van Handel M, Zhang L, Nadkarni N, Badie B: Impaired capacity for upregulation of MHC class II in tumor-associated microglia. Glia. 2005, 51: 279-85. 10.1002/glia.20201.CrossRefPubMed
20.
go back to reference Waziri A, Killory B, Ogden AT, Canoll P, Anderson RC, Kent SC, Anderson DE, Bruce JN: Preferential in situ CD4+CD56+ T cell activation and expansion within human glioblastoma. J Immunol. 2008, 180: 7673-80.CrossRefPubMed Waziri A, Killory B, Ogden AT, Canoll P, Anderson RC, Kent SC, Anderson DE, Bruce JN: Preferential in situ CD4+CD56+ T cell activation and expansion within human glioblastoma. J Immunol. 2008, 180: 7673-80.CrossRefPubMed
21.
go back to reference El Andaloussi A, Lesniak MS: An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol. 2006, 8: 234-43. 10.1215/15228517-2006-006.CrossRefPubMed El Andaloussi A, Lesniak MS: An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol. 2006, 8: 234-43. 10.1215/15228517-2006-006.CrossRefPubMed
22.
go back to reference El Andaloussi A, Lesniak MS: CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol. 2007, 83: 145-52. 10.1007/s11060-006-9314-y.CrossRefPubMed El Andaloussi A, Lesniak MS: CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol. 2007, 83: 145-52. 10.1007/s11060-006-9314-y.CrossRefPubMed
23.
go back to reference Ogden AT, Horgan D, Waziri A, Anderson D, Louca J, McKhann GM, Sisti MB, Parsa AT, Bruce JN: Defective receptor expression and dendritic cell differentiation of monocytes in glioblastomas. Neurosurgery. 2006, 59: 902-9. 10.1227/01.NEU.0000233907.03070.7B. discussion 909–10CrossRefPubMed Ogden AT, Horgan D, Waziri A, Anderson D, Louca J, McKhann GM, Sisti MB, Parsa AT, Bruce JN: Defective receptor expression and dendritic cell differentiation of monocytes in glioblastomas. Neurosurgery. 2006, 59: 902-9. 10.1227/01.NEU.0000233907.03070.7B. discussion 909–10CrossRefPubMed
24.
go back to reference Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, Herndon JE, Bigner DD, Dranoff G, Sampson JH: Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006, 66: 3294-302. 10.1158/0008-5472.CAN-05-3773.CrossRefPubMed Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, Herndon JE, Bigner DD, Dranoff G, Sampson JH: Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006, 66: 3294-302. 10.1158/0008-5472.CAN-05-3773.CrossRefPubMed
25.
go back to reference Learn CA, Fecci PE, Schmittling RJ, Xie W, Karikari I, Mitchell DA, Archer GE, Wei Z, Dressman H, Sampson JH: Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers. Clin Cancer Res. 2006, 12: 7306-15. 10.1158/1078-0432.CCR-06-1727.CrossRefPubMed Learn CA, Fecci PE, Schmittling RJ, Xie W, Karikari I, Mitchell DA, Archer GE, Wei Z, Dressman H, Sampson JH: Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers. Clin Cancer Res. 2006, 12: 7306-15. 10.1158/1078-0432.CCR-06-1727.CrossRefPubMed
26.
go back to reference Sonabend AM, Rolle CE, Lesniak MS: The role of regulatory T cells in malignant glioma. Anticancer Res. 2008, 28: 1143-50.PubMed Sonabend AM, Rolle CE, Lesniak MS: The role of regulatory T cells in malignant glioma. Anticancer Res. 2008, 28: 1143-50.PubMed
27.
go back to reference Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Sun W, Qiao W, Hiraoka N, Fuller GN: Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res. 2008, 14: 5166-72. 10.1158/1078-0432.CCR-08-0320.CrossRefPubMed Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Sun W, Qiao W, Hiraoka N, Fuller GN: Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res. 2008, 14: 5166-72. 10.1158/1078-0432.CCR-08-0320.CrossRefPubMed
28.
go back to reference Jordan JT, Sun W, Hussain SF, DeAngulo G, Prabhu SS, Heimberger AB: Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother. 2008, 57: 123-31. 10.1007/s00262-007-0336-x.CrossRefPubMed Jordan JT, Sun W, Hussain SF, DeAngulo G, Prabhu SS, Heimberger AB: Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother. 2008, 57: 123-31. 10.1007/s00262-007-0336-x.CrossRefPubMed
29.
go back to reference El Andaloussi A, Han Y, Lesniak MS: Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg. 2006, 105: 430-7. 10.3171/jns.2006.105.3.430.CrossRefPubMed El Andaloussi A, Han Y, Lesniak MS: Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg. 2006, 105: 430-7. 10.3171/jns.2006.105.3.430.CrossRefPubMed
30.
go back to reference Klebanoff CA, Gattinoni L, Restifo NP: CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006, 211: 214-24. 10.1111/j.0105-2896.2006.00391.x.PubMedCentralCrossRefPubMed Klebanoff CA, Gattinoni L, Restifo NP: CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006, 211: 214-24. 10.1111/j.0105-2896.2006.00391.x.PubMedCentralCrossRefPubMed
31.
go back to reference Uhrbom L, Hesselager G, Nister M, Westermark B: Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res. 1998, 58: 5275-9.PubMed Uhrbom L, Hesselager G, Nister M, Westermark B: Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res. 1998, 58: 5275-9.PubMed
32.
go back to reference Shih AH, Dai C, Hu X, Rosenblum MK, Koutcher JA, Holland EC: Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res. 2004, 64: 4783-9. 10.1158/0008-5472.CAN-03-3831.CrossRefPubMed Shih AH, Dai C, Hu X, Rosenblum MK, Koutcher JA, Holland EC: Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res. 2004, 64: 4783-9. 10.1158/0008-5472.CAN-03-3831.CrossRefPubMed
33.
go back to reference Assanah M, Lochhead R, Ogden A, Bruce J, Goldman J, Canoll P: Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. J Neurosci. 2006, 26: 6781-90. 10.1523/JNEUROSCI.0514-06.2006.CrossRefPubMed Assanah M, Lochhead R, Ogden A, Bruce J, Goldman J, Canoll P: Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. J Neurosci. 2006, 26: 6781-90. 10.1523/JNEUROSCI.0514-06.2006.CrossRefPubMed
Metadata
Title
Dynamics of central and peripheral immunomodulation in a murine glioma model
Authors
Benjamin C Kennedy
Lisa M Maier
Randy D'Amico
Christopher E Mandigo
Elizabeth J Fontana
Allen Waziri
Marcela C Assanah
Peter Canoll
Richard CE Anderson
David E Anderson
Jeffrey N Bruce
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Immunology / Issue 1/2009
Electronic ISSN: 1471-2172
DOI
https://doi.org/10.1186/1471-2172-10-11

Other articles of this Issue 1/2009

BMC Immunology 1/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine